Cargando…

Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations

Inhibitors of monoamine oxidase B (MAO-B) and catechol-O-methyltransferase (COMT) are major strategies to reduce levodopa degradation and thus to increase and prolong its effect in striatal dopaminergic neurotransmission in Parkinson’s disease patients. While selegiline/rasagiline and tolcapone/enta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Regensburger, Martin, Ip, Chi Wang, Kohl, Zacharias, Schrader, Christoph, Urban, Peter P., Kassubek, Jan, Jost, Wolfgang H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2023
Materias:	Neurology and Preclinical Neurological Studies - Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199833/ https://www.ncbi.nlm.nih.gov/pubmed/36964457 http://dx.doi.org/10.1007/s00702-023-02623-8

Ejemplares similares

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease
por: Jost, Wolfgang H.
Publicado: (2022)

Life style and Parkinson’s disease
por: Reichmann, Heinz, et al.
Publicado: (2022)

Parkinson’s disease between internal medicine and neurology
por: Csoti, Ilona, et al.
Publicado: (2015)

Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty
por: Auffret, Manon, et al.
Publicado: (2023)

Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study
por: Zagnoli, Fabien, et al.
Publicado: (2023)

Implications of dopaminergic medication withdrawal in Parkinson’s disease
por: Koschel, J., et al.
Publicado: (2021)

Treadmill training and physiotherapy similarly improve dual task gait performance: a randomized-controlled trial in Parkinson’s disease
por: Gaßner, Heiko, et al.
Publicado: (2022)

Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome
por: Grund, K. E., et al.
Publicado: (2023)

Relevance of sonography for botulinum toxin treatment of cervical dystonia: an expert statement
por: Schramm, Axel, et al.
Publicado: (2014)

The heterogeneity of Parkinson’s disease
por: Wüllner, Ullrich, et al.
Publicado: (2023)

Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease
por: Jenner, P., et al.
Publicado: (2023)

Genetic testing for Parkinson’s disease in clinical practice
por: Gasser, Thomas
Publicado: (2023)

Blood neurofilament light chain in Parkinson’s disease
por: Buhmann, Carsten, et al.
Publicado: (2023)

Apprends-moi l'art des petits pas: Levodopa, Carbidopa Intestinal Gel plus Entacapone
por: Jost, Wolfgang H.
Publicado: (2023)

Viruses, parkinsonism and Parkinson’s disease: the past, present and future
por: Leta, Valentina, et al.
Publicado: (2022)

Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice
por: Tönges, Lars, et al.
Publicado: (2022)

Glucocerebrosidase mutations and Parkinson disease
por: Vieira, Sophia R. L., et al.
Publicado: (2022)

Parkinsonism in Inherited Metabolic Disorders: Key Considerations and Major Features
por: Limphaibool, Nattakarn, et al.
Publicado: (2018)

Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience
por: Henriksen, Tove, et al.
Publicado: (2023)

Significance of clinical symptoms and red flags in early differential diagnosis of Parkinson’s disease and atypical Parkinsonian syndromes
por: Schröter, Nils, et al.
Publicado: (2023)

Treatment of Parkinson’s disease in the advanced stage
por: Ossig, C., et al.
Publicado: (2013)

Small intestine dysfunction in Parkinson’s disease
por: Dutkiewicz, Justyna, et al.
Publicado: (2015)

Neuroprotection in Parkinson’s disease: facts and hopes
por: Salamon, András, et al.
Publicado: (2019)

Best practice approaches to outpatient management of people living with Parkinson’s disease during the COVID-19 pandemic
por: Demleitner, Antonia F., et al.
Publicado: (2022)

Dysphagia in cervical dystonia patients receiving optimised botulinum toxin therapy: a single-center retrospective cohort study
por: Kutschenko, Anna, et al.
Publicado: (2020)

Sleep and non-motor symptoms in Parkinson’s disease
por: Maass, Antonia, et al.
Publicado: (2013)

Magnetic resonance imaging for the diagnosis of Parkinson’s disease
por: Heim, Beatrice, et al.
Publicado: (2017)

Disease modification in Parkinsonism: obstacles and ways forward
por: Höllerhage, M., et al.
Publicado: (2022)

The use of wearables for the diagnosis and treatment of Parkinson’s disease
por: Reichmann, Heinz, et al.
Publicado: (2023)

Parkinson’s disease therapy: what lies ahead?
por: Wolff, Andreas, et al.
Publicado: (2023)

Serum neurofilament light chain and postural instability/gait difficulty (PIGD) subtypes of Parkinson’s disease in the MARK-PD study
por: Pötter-Nerger, Monika, et al.
Publicado: (2022)

Non-motor symptoms of Parkinson’s disease: the patient’s perspective
por: Breen, Kieran C., et al.
Publicado: (2012)

Flavor perception and the risk of malnutrition in patients with Parkinson’s disease
por: Roos, Dareia S., et al.
Publicado: (2018)

Parkinson’s: a syndrome rather than a disease?
por: Titova, Nataliya, et al.
Publicado: (2016)

Diagnostic accuracy of glabellar tap sign for Parkinson’s disease
por: Nuuttila, Simo, et al.
Publicado: (2021)

The pathobiological basis of depression in Parkinson disease: challenges and outlooks
por: Jellinger, Kurt A.
Publicado: (2022)

Gender differences in non-motor fluctuations in Parkinson’s disease
por: Donzuso, Giulia, et al.
Publicado: (2023)

Current and novel infusion therapies for patients with Parkinson's disease
por: Antonini, Angelo, et al.
Publicado: (2023)

Impact of early intervention with onabotulinumtoxinA treatment in adult patients with post-stroke lower limb spasticity: results from the double-blind, placebo-controlled, phase 3 REFLEX study
por: Patel, Atul T., et al.
Publicado: (2020)

Diagnostic biomarkers for Parkinson’s disease at a glance: where are we?
por: Cova, Ilaria, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c85qetn11n2andpf7iqf9a7q2a